Featured Stories
Fast And Furious: How The First-To-Market Advantage Is Shrinking
The competitive dynamics in the pharmaceutical sector appear to be intensifying, with second- and third-to-market drugs reaching the market faster behind first-in-class drugs. That's putting more pressure on new drug launches and impacting drug pricing and rebating strategies.
Spotlight On Israel: Market Challenges Stunting Biopharma Growth
Scrip investigates the big issues Israel's biopharma sector need to overcome in order to maintain momentum and achieve sustainable success.
Sweet Enough? Takeda Raises, Adds Cash To Shire Offer
Takeda has further bumped up its offer for acquisition target Shire, raising the per share price and cash component, in what the Japanese firm says is a “compelling” proposal worth well over $60bn. Will it be fourth time lucky?
Latest News
Recent Tweets from Scrip
Polyglucoferron: A New Benchmark For IV Iron Treatment
Iron4u, a pharmaceutical company founded in 2012 by investors from five European countries and based just outside Copenhagen, Denmark, have developed an innovative high-dose IV iron product for the treatment of iron deficiency or iron-deficiency anemia. They believe Polyglucoferron could set a new benchmark in the field of intravenous iron therapy. Developed in partnership with the German company Serumwerk Bernburg, the product is now in Phase III clinical trials for human use as an injection or infusion.
Commercial Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Stock Scan Q1 2018: A Slump And A Proper Correction
The story of the first quarter of 2018 is the impact of the general stock downturn at the end of January and the selective recovery that followed. But even though AbbVie and others had their own private yo-yos, the real correction took a while.
Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
Investors await news from Lilly on whether it will use repatriated cash for M&A; from Biogen on its Spinraza and gene therapy strategies in light of Novartis' AveXis deal; and from Amgen on pipeline programs and acquisitions as major products face new competition. Immuno-oncology combination updates are anticipated from Roche, plus guidance on how GSK will cope with Advair generics, HIV competition from Gilead and the cost of new drug launches is expected.
Oncology Venture Differentiates Using Big Data Systems Biology
With six oncology assets in Phase II/III ready for outlicensing, Oncology Venture is now looking to take additional programs on board.
Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns
Win-Win For Alnylam And Dicerna With RNAi Trade Secrets Settlement
Although Dicerna needs to make some payments to Alnylam to settle a patent infringement case, the company has avoided an expensive court trial and is free to find partners for its early-stage RNAi therapeutics programs.
AstraZeneca Seeks To Ward Off Brilinta Patent Infringer In India
An Indian court has blocked an alleged infringer of AstraZeneca's patent pertaining to Brilinta (ticagrelor), but the case, some experts claim, also brings to the fore certain controversial tactics at play in the legal arena as large firms pursue litigation to safeguard their intellectual property.
ADAPT Or Die: Argos Therapeutics On Brink After Phase III Failure
The US firm brings in advisors as it considers its options after the Phase III ADAPT study of its cancer immunotherapy fails even after change to protocol.
New Active Substance First Launches Rebound In 2017
2017 was the second-best year for new drug launches worldwide since the start of the millennium, new research by Informa Pharma Intelligence's Pharmaprojects has found.
Policy & Regulation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Lilly May Need To Reassess Baricitinib Market After FDA Advisory Committee
During a mixed review by the US FDA's Arthritis Advisory Committee, panelists suggested that risks potentially associated with Lilly/Incyte's JAK inhibitor would be acceptable for a more limited patient population.
China Vs Cancer: An Infographic Snapshot
Cancer cases are rising in China, with larger increases for certain types including thyroid and pancreatic. To combat the rising tide, the government will implement zero tariffs on imported anticancer drugs from May.
Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst
The US FDA gives Sweden's privately held Modus Therapeutics rare pediatric disease designation for sickle cell disease.
India Leads Global 65% Surge In Antibiotics Use
Human antibiotic consumption globally jumped dramatically between 2000 and 2015, with India posting the biggest rise, reports a new US study, which calls for a radical policy rethink to prevent antimicrobial drug resistance soaring.
Research & Development Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Synthetic Biologics’ Ribaxamase Setback Shows Difficulty Of C. Difficile Development
Company believes there is a path forward for developing ribaxamase in Phase III, based on discussions with the FDA, but deaths in Phase II meant loss of breakthrough designation.
Glenmark Eyes Blockbuster Status For First In-House Biologic
Indian drug firm Glenmark Pharmaceuticals says it’s launching a Phase 2b clinical trial for its first biologic developed in-house, a medicine to treat atopic dermatitis that the company believes may have blockbuster potential.
ADAPT Or Die: Argos Therapeutics On Brink After Phase III Failure
The US firm brings in advisors as it considers its options after the Phase III ADAPT study of its cancer immunotherapy fails even after change to protocol.
Next-Generation CAR-Ts Tackle First-Generation Safety, Solid Tumor Challenges
New strategies to overcome safety, solid tumor and other challenges associated with CAR-T therapies – and some early clinical data for patients treated with Poseida's, Celyad's and Autolus' novel products – were featured at the American Association for Cancer Research (AACR) meeting.
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.